Inpharma Weekly

, Volume 1379, Issue 1, pp 5–5 | Cite as

Is DOTS-plus worth it for TB in developing countries?

Clinical study
  • 4 Downloads

Keywords

Tuberculosis Hypothetical Cohort Antituberculosis Drug Additional Individual Acceptable Cost 

Copyright information

© Adis International Ltd 2003

Personalised recommendations